CL2022001583A1 - Derivados espiráncos sustituidos de cadena lineal - Google Patents

Derivados espiráncos sustituidos de cadena lineal

Info

Publication number
CL2022001583A1
CL2022001583A1 CL2022001583A CL2022001583A CL2022001583A1 CL 2022001583 A1 CL2022001583 A1 CL 2022001583A1 CL 2022001583 A CL2022001583 A CL 2022001583A CL 2022001583 A CL2022001583 A CL 2022001583A CL 2022001583 A1 CL2022001583 A1 CL 2022001583A1
Authority
CL
Chile
Prior art keywords
spiranchic
derivatives
straight
chain substituted
protein
Prior art date
Application number
CL2022001583A
Other languages
English (en)
Inventor
Yanping Xu
Vineet Pande
Wei Cai
Xuedong Dai
Olivier Alexis Georges Querolle
Johannes Wilhelmus John F Thuring
Yingtao Liu
Lianzhu Liu
Liqiang Fu
Ming Li
Lichao Fang
Xiangjun Deng
Qiwu Zhao
Kangying Li
Alicia Tee Fuay Ng
Nicolas Freddy J Darville
Edward Cleator
Gregor Thomas Urbanietz
William Marc Maton
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2022001583A1 publication Critical patent/CL2022001583A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción proteína/proteína de la menina/MLL, útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
CL2022001583A 2019-12-19 2022-06-13 Derivados espiráncos sustituidos de cadena lineal CL2022001583A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04

Publications (1)

Publication Number Publication Date
CL2022001583A1 true CL2022001583A1 (es) 2023-02-03

Family

ID=76476870

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2022001583A CL2022001583A1 (es) 2019-12-19 2022-06-13 Derivados espiráncos sustituidos de cadena lineal
CL2023001531A CL2023001531A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal
CL2023001530A CL2023001530A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2023001531A CL2023001531A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal
CL2023001530A CL2023001530A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal

Country Status (19)

Country Link
US (1) US20230142285A1 (es)
EP (1) EP4077312A4 (es)
JP (1) JP2023506530A (es)
KR (1) KR20220118500A (es)
CN (1) CN114867721A (es)
AU (1) AU2020404305A1 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965A (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
TW (1) TW202138367A (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
WO2022237627A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
EP4337216A1 (en) 2021-05-11 2024-03-20 JANSSEN Pharmaceutica NV Combination therapies
EP4337215A1 (en) 2021-05-11 2024-03-20 JANSSEN Pharmaceutica NV Combination therapies
KR20240016324A (ko) 2021-06-01 2024-02-06 얀센 파마슈티카 엔브이 치환된 페닐-1H-피롤로[2,3-c]피리딘 유도체
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
EP4355747A1 (en) * 2021-06-17 2024-04-24 JANSSEN Pharmaceutica NV (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2023098876A1 (en) * 2021-12-03 2023-06-08 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) * 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
WO2016000581A1 (zh) * 2014-07-04 2016-01-07 南京明德新药研发股份有限公司 螺环芳基磷氧化物和芳基磷硫化物
CN105330698B (zh) * 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
US20170275302A1 (en) * 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
MX2018007703A (es) * 2015-12-22 2018-11-09 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-linaje leucemico mixto.
KR102436430B1 (ko) * 2016-06-10 2022-08-24 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
SI3512857T1 (sl) * 2016-09-14 2021-07-30 Janssen Pharmaceutica Nv Spiro biciklični zaviralci interakcije menin-MLL
DK3512850T3 (da) * 2016-09-16 2023-07-03 Vitae Pharmaceuticals Llc Inhibitorer af menin-mll-interaktionen
US11944627B2 (en) * 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) * 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3684361A4 (en) * 2017-09-20 2021-09-08 Kura Oncology, Inc. MENINE-MLL SUBSTITUTE INHIBITORS AND METHODS OF USE
EP3856173A4 (en) * 2018-09-26 2022-07-06 Kura Oncology, Inc. TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENIN INHIBITORS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor

Also Published As

Publication number Publication date
UY38988A (es) 2021-06-30
WO2021121327A1 (en) 2021-06-24
PE20230162A1 (es) 2023-02-01
EP4077312A4 (en) 2024-01-17
CO2022009085A2 (es) 2022-07-08
TW202138367A (zh) 2021-10-16
CN114867721A (zh) 2022-08-05
JP2023506530A (ja) 2023-02-16
CR20220346A (es) 2022-10-26
DOP2022000125A (es) 2022-08-31
AU2020404305A1 (en) 2022-08-04
KR20220118500A (ko) 2022-08-25
IL293965A (en) 2022-08-01
US20230142285A1 (en) 2023-05-11
JOP20220154A1 (ar) 2023-01-30
CL2023001530A1 (es) 2023-11-03
ECSP22054700A (es) 2022-11-30
MX2022007652A (es) 2022-09-23
EP4077312A1 (en) 2022-10-26
CL2023001531A1 (es) 2023-11-03
CA3161045A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
CL2022001583A1 (es) Derivados espiráncos sustituidos de cadena lineal
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
UY39795A (es) DERIVADOS DE FENIL-1H-PIRROLO[2,3-c]PIRIDINA SUSTITUIDOS
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
UY35293A (es) Isotiazoles sustituidos con amino
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
CL2008003222A1 (es) Peptidos con actividad antagonista de glucagon y composicion farmaceutica que los comprende, utiles para el tratamiento de la hiperglicemia, para suprimir el apetito, reducir el aumento de peso y para tratar el desgaste catabolico.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
DOP2017000142A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos, composiciones que los contienen y usos de los mismos
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2023013174A (es) Derivados espiro sustituidos.
MX2023013176A (es) Derivados espiro sustituidos.
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer
CL2011000647A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de enlace de la proteina smac al iap; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades proliferativas. (divisional de la solicitud 2234-2007).
CL2011000645A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; y composicion farmaceutica que los comprende; y su uso en eltratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
CL2011000646A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; composicion farmaceutica que los comprende; util en el tratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
AR044808A1 (es) Derivados de triazolopirimidina y pirimidianilidas y su uso en una mezcla fungicida
BR112016019511A8 (pt) Inibidores de jak1 para o tratamento de síndromes mielodisplásicas